Background: Intermittent dobutamine infusions(IDI) combined with oral amiodarone improve the survival of patients with end-stage congestive heart failure(CHF). The purpose of the present study was to evaluate whether ...Background: Intermittent dobutamine infusions(IDI) combined with oral amiodarone improve the survival of patients with end-stage congestive heart failure(CHF). The purpose of the present study was to evaluate whether the response to longterm treatment with IDI + amiodarone is different in patients with ischemic heart disease(IHD) versus idiopathic dilated cardiomyopathy(IDC).Methods: The prospective study population consisted of 21 patients with IHD(the IHD Group) and 16 patients with IDC(the IDC Group) who presented with decompensated CHF despite optimal medical therapy, and were successfully weaned from an initial 72-h infusion of dobutamine. They were placed on a regimen of oral amiodarone, 400 mg/day and weekly IDI, 10 μ g/kg/min, for 8 h. Results: There were no differences in baseline clinical and hemodynamic characteristics between the 2 groups. The probability of 2-year survival was 44% in the IDC Group versus 5% in the IHD Group(long-rank, P=0.004). Patients with IDC had a 77% relative risk reduction in death from all causes compared to patients with IHD(odd ratio 0.27, 95% confidence interval 0.13 to 0.70, P=0.007). In contrast, no underlying disease-related difference in outcomes was observed in a retrospectively analyzed historical Comparison Group of 29 patients with end stage CHF treated by standard methods. Conclusions: Patients with end stage CHF due to IDC derived a greater survival benefit from IDI and oral amiodarone than patients with IHD.展开更多
文摘Background: Intermittent dobutamine infusions(IDI) combined with oral amiodarone improve the survival of patients with end-stage congestive heart failure(CHF). The purpose of the present study was to evaluate whether the response to longterm treatment with IDI + amiodarone is different in patients with ischemic heart disease(IHD) versus idiopathic dilated cardiomyopathy(IDC).Methods: The prospective study population consisted of 21 patients with IHD(the IHD Group) and 16 patients with IDC(the IDC Group) who presented with decompensated CHF despite optimal medical therapy, and were successfully weaned from an initial 72-h infusion of dobutamine. They were placed on a regimen of oral amiodarone, 400 mg/day and weekly IDI, 10 μ g/kg/min, for 8 h. Results: There were no differences in baseline clinical and hemodynamic characteristics between the 2 groups. The probability of 2-year survival was 44% in the IDC Group versus 5% in the IHD Group(long-rank, P=0.004). Patients with IDC had a 77% relative risk reduction in death from all causes compared to patients with IHD(odd ratio 0.27, 95% confidence interval 0.13 to 0.70, P=0.007). In contrast, no underlying disease-related difference in outcomes was observed in a retrospectively analyzed historical Comparison Group of 29 patients with end stage CHF treated by standard methods. Conclusions: Patients with end stage CHF due to IDC derived a greater survival benefit from IDI and oral amiodarone than patients with IHD.
